RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES
H7536 requires most Rhode Island health coverage arrangements to reimburse pharmacists for certain clinical services when those services are within the lawful scope of pharmacy practice and would otherwise be covered if performed by a physician, advanced practice nurse, or physician assistant. The bill applies to group health insurance contracts, nonprofit medical service corporations, and health maintenance organizations, and it also directs the state Medicaid program to establish comparable coverage. Covered pharmacist services include patient evaluation and management, medication therapy management, immunization education and administration, medication administration, and ordering and evaluating clinical laboratory tests.
The bill also prohibits insurers from requiring supervision, a signature, or a referral from another health care provider as a condition of paying a pharmacist, while preventing duplicate payment for the same service when it is already rendered by another provider. It requires plans to include an adequate number of pharmacists in their provider networks and allows out-of-network coverage when the needed pharmacist service is not available in-network. The measure takes effect January 1, 2027, and sunsets January 1, 2031, unless extended by the General Assembly.
If enacted, the bill would amend multiple chapters of Rhode Island insurance and Medicaid law, including provisions governing accident and sickness insurance policies, nonprofit hospital service corporations, nonprofit medical service corporations, health maintenance organizations, and medical assistance. It would create a new statutory coverage mandate for pharmacist-provided clinical services and require the executive office of health and human services to seek any necessary Medicaid state plan amendment or waiver, with a submission deadline of September 1, 2026. The bill would also impose network adequacy expectations for pharmacists as participating medical providers and establish a temporary statewide policy through 2031.
Based on the bill text and available context, the measure appears to have a generally supportive policy rationale centered on expanding access to care and recognizing pharmacists as reimbursable clinical providers. The bill’s structure suggests an effort to align payment rules across commercial insurance and Medicaid, indicating a broad health-system approach rather than a narrow professional carveout. No committee transcript or vote record was provided, so there is no documented opposition or recorded sentiment from debate in the available materials.
The main points of potential contention are likely to be insurer reimbursement obligations, network adequacy requirements, and the scope of pharmacist billing authority. Insurers and nonprofit medical service corporations may object to being required to pay pharmacists directly for services that could also be performed by physicians, APRNs, or physician assistants, especially where the bill limits their ability to require referral or supervision. Another likely issue is the bill’s treatment of duplicate services and the requirement to include pharmacists in provider networks, which could raise administrative and cost concerns. Supporters would likely emphasize expanded access, especially for immunizations, medication management, and basic clinical services, while opponents may focus on cost, utilization, and coordination-of-care concerns.